Pulmonary arterial hypertension: classification, diagnosis and contemporary management
暂无分享,去创建一个
R. Khattar | D. Fox | D J Fox | R S Khattar
[1] J. Loscalzo,et al. Pulmonary arterial hypertension. , 2004, Annals of medicine.
[2] F. Martinez,et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[3] Horst Olschewski,et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.
[4] D. Mccrory,et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[5] L. Rubin. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[6] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[7] W. Krause,et al. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man , 2004, European Journal of Clinical Pharmacology.
[8] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[9] G. Funk,et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.
[10] S. Rich,et al. Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.
[11] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[12] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[13] C. Narasimhan,et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.
[14] S. Rich,et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.
[15] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[16] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[17] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[18] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[19] F. Orzan,et al. Primary Pulmonary Hypertension , 2000, Minerva cardioangiologica.
[20] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[21] C. Pedersen,et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. , 2000, The European respiratory journal.
[22] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[23] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .
[24] W R Clarke,et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.
[25] J. Sandoval,et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.
[26] M. Maclean. Endothelin-1: a mediator of pulmonary hypertension? , 1998, Pulmonary pharmacology & therapeutics.
[27] Keith McNeil,et al. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). , 1998, American journal of respiratory and critical care medicine.
[28] F RANKLIN H. E PSTEIN,et al. INFLAMMATORY DISEASE , 2022 .
[29] R. Dixon,et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. , 1997, Journal of Medicinal Chemistry.
[30] W. Gersony,et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. , 1995, Circulation.
[31] A. Denjean,et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.
[32] T. E. Schultz,et al. Pulmonary hypertension and HIV infection: new observations and review of the syndrome. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[33] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[34] T. McMahon,et al. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. , 1993, Journal of applied physiology.
[35] S. Soifer,et al. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. , 1993, The American journal of physiology.
[36] S. Shinohara,et al. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. , 1992, Japanese circulation journal.
[37] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[38] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[39] D. Buff. Primary pulmonary hypertension. , 1987, Annals of internal medicine.
[40] J. Seward,et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. , 1985, Journal of the American College of Cardiology.
[41] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.
[42] K. Moser,et al. Perfusion lung scans vs pulmonary angiography in evaluation of suspected primary pulmonary hypertension. , 1983, Chest.
[43] J. Schroeder,et al. Diazoxide in treatment of primary pulmonary hypertension. , 1979, British heart journal.